Nick Slavin

I’m co-founder and CEO of Fuzionaire Theranostics, where we’re developing silicon-based radioligand therapies and PET diagnostics for cancer, and Fuzionaire, an R&D lab spun out of Nobel laureate Robert Grubbs’ lab at Caltech. As of 2025, our collaborations span four continents and our targeted therapies and PET imaging agents are being tested in cancer patients in Germany on a compassionate use basis. Our HetSiFA platform enables improved manufacturing and fine-tuned, personalized dosimetry for cancer theranostics.

Outside of Fuzionaire, I’m founder and chairman of the Slavin Family Foundation, whose Slavin Fellowships support outstanding student entrepreneurs. Launched in 2015, our 61 fellows to date include Rhodes Scholars, Schwarzman Scholars, Thiel Fellows, 8 exited founders, and founders and creators in many disciplines from schools around the world. The Fellowship was created in part as a counterpoint to the Thiel Fellowship in its support of student founders without requiring they drop out of school.

I’m also co-founder of the Arch Mission Foundation (AMF), which is backing up humanity’s knowledge and biology in billion-year data storage devices across the solar system. AMF has partnered in eight missions, including two Moon landings, with SpaceX, Blue Origin, and NASA. AMF’s first Arch Library, containing Isaac Asimov’s Foundation Trilogy, was launched by SpaceX on the Falcon Heavy test launch in 2018 and is now in solar orbit. AMF’s Lunar Library I landed on the Moon in 2019. A copy is on display in the Smithsonian’s National Air and Space Museum, in the Futures in Space exhibit. In 2024, the Lunar Library II landed on the Moon.

Previously, I did mergers and acquisitions as a lawyer at Skadden Arps, which at the time had been ranked the #1 corporate law firm by Corporate Board Member magazine for 14 consecutive years.

I’m a graduate of Harvard Law and Yale College, where I started my first company out of economics research (later acquired) and graduated magna cum laude and Phi Beta Kappa at 19.